This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Betty S. Sutherland, MD; Helen K. Berry, MA; Barbara Umbarger, MA

JAMA. 1970;211(2):270-276.

Abstract
Nutritional, clinical, and laboratory data collected over a period of years were examined to explain growth rate changes in children treated for phenylketonuria. The data suggest that periods of inconstant growth, associated clinical symptoms, and elevations of serum phenylalanine levels were related to an imbalance between essential amino acids in a commercial, low-phenylalanine, protein substitute (Lofenalac) and phenylalanine in natural food sources. Growth stability, clinical well-being, and stable levels of serum phenylalanine were obtained by providing both the protein substitute in amounts adequate to meet the recommended protein requirement for growth, and sufficient phenylalanine from natural sources to balance the other essential amino acids in the protein substitute.

Author Affiliations
From the Children's Hospital Research Foundation, Institute for Developmental Research and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati.

Footnotes
Reprint requests to 240 Elland Ave, Cincinnati 45229 (Dr. Sutherland).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Hyperuricemia Among Kuwaitis
Ali et al.
Arch Intern Med 1996;156:2381-2386.
ABSTRACT  

Nutritional Management in Phenylketonuria
Hunt et al.
Arch Pediatr Adolesc Med 1971;122:1-6.
ABSTRACT  

Cognitive Development in Early Treated Phenylketonuria
O'Grady et al.
Arch Pediatr Adolesc Med 1971;121:20-23.
ABSTRACT